Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02978716
Previous Study | Return to List | Next Study

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02978716
Recruitment Status : Active, not recruiting
First Posted : December 1, 2016
Last Update Posted : July 26, 2019
Sponsor:
Information provided by (Responsible Party):
G1 Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 30, 2018
Estimated Study Completion Date : June 2020
Certification/Extension First Submitted : July 18, 2019